| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -18,879,077 | -11,152,438 |
| Accretion of discount on marketable securities, net | 708,019 | 486,494 |
| Stock-based compensation expense | 1,149,899 | 858,182 |
| Prepaid expenses and other assets | -219,388 | 58,967 |
| Deferred grant revenue | - | 0 |
| Deferred offering costs | 269,331 | 163,354 |
| Accounts payable | -162,221 | 272,592 |
| Accrued expenses and other current liabilities | 882,253 | 428,169 |
| Grant receivable | -892,844 | 106,744 |
| Net cash used in operating activities | -16,874,264 | -10,409,054 |
| Purchase of marketable securities | 20,776,519 | 16,858,416 |
| Maturities of marketable securities | 33,500,000 | 22,000,000 |
| Net cash provided by (used in) investing activities | 12,723,481 | 5,141,584 |
| Proceeds from the sale of common stock, prefunded warrants and common stock warrants, net of offering costs | 0 | 0 |
| Sale of common stock under open market sales agreement, net of issuance costs-Open Market Sales Agreement | 4,588,687 | 4,588,687 |
| Net cash provided by financing activities | 4,588,687 | 4,588,687 |
| Net increase (decrease) in cash and cash equivalents | 437,904 | -678,783 |
| Cash and cash equivalents at beginning of period | 8,999,496 | - |
| Cash and cash equivalents at end of period | 9,437,400 | - |
CervoMed Inc. (CRVO)
CervoMed Inc. (CRVO)